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PENGOPTIMUMAN PENGHASILAN ALKOHOL KIRAL MELALUI 
BIOTRANSFORMASI 1-(4-BROMO-FENIL)-ETANON BERMANGKINKAN 
KULAT ASPERGILLUS NIGER 
 
ABSTRAK 
 
Alkohol kiral merupakan bahan permulaan yang sangat berguna untuk 
penghasilan pelbagai sebatian biologi yang aktif. Dalam kajian ini, penurunan keton 
bermangkinkan biologi melalui proses penurunan tidak simetri menggunakan 
Aspergillus niger sebagai pemangkin biologi telah dijalankan bagi menghasilkan (R)-
1-(4-bromo-fenil)-etanol. Daripada hasil kajian ini, didapati fasa eksponen adalah 
masa yang terbaik bagi proses biotransformasi jika dibandingkan dengan fasa pegun 
kerana kadar penghasilan pada fasa eksponen (0.063 mM/j) lebih tinggi daripada fasa 
pegun (0.028 mM/j). Tambahan pula, kajian pengoptimuman biotransformasi yang 
dilakukan melalui sistem kelalang goncang menunjukkan bahawa keadaan optimum 
yang didapati ialah pada jam yang ke 48 masa pengeraman, pH 6.68, suhu 31.85
o
C 
dengan kepekatan substrat yang rendah iaitu 6.78 mM. Lebihan enantiomer dan 
penukaran produk adalah sangat tinggi pada keadaan optimum ini iaitu hampir 100 
%. Penambahan amaun kepekatan substrat dalam proses biotransformasi ini telah 
menyebabkan berlakunya rencatan substrat. Tambahan pula dengan menggunakan 
2.5 L sistem bioreaktor, ianya boleh memaksimumkan peratusan lebihan enantiomer, 
penukaran produk dan juga kadar penghasilan produk. Parameter-parameter yang 
dikaji dalam sistem bioreaktor ialah kelajuan pengadukan pada kadar 50 rpm ke 150 
rpm dan juga masa pengeraman biotransformasi dari 0 hingga ke 56 jam. Daripada 
keputusan kajian yang didapati, kelajuan pengadukan yang maksimum ialah pada 
xxii 
 
tahap 150 rpm dengan masa pengeraman optimumnya pada jam ke 33.34 proses 
biotransformasi yang mana menghasilkan 99.94 % lebihan enantiomer dan 88.82 %  
penukaran produk. Tambahan pula, sebanyak 0.097 mM/j kadar penghasilan (R)-1-
(4-bromo-fenil)-etanol telah dicapai pada keadaan optimum ini. Oleh yang demikian, 
daripada keputusan kajian yang diperolehi, ianya secara jelas menunjukkan bahawa, 
terdapat perbezaan yang ketara dalam kadar penghasilan dan juga penukaran produk 
(R)-1-(4-bromo-fenil)-etanol dengan menggunakan sistem bioreaktor. Masa 
pengoptimuman juga boleh dipendekkan jika dibandingkan dengan sistem kelalang 
goncang. Keputusan kajian yang diperolehi daripada sistem bioreaktor boleh 
digunakan untuk kajian-kajian lain pada masa akan datang seperti kajian 
menggunakan pelbagai jenis substrat, pengaliran udara yang berbeza dan pelbagai 
jenis pemangkin biologi. Selain itu, bagi kajian kinetik penapaian, kadar spesifik 
pertumbuhan, (µ)  A. niger ialah 0.29/j dengan 0.164/j kadar pembentukan produk, 
(qp) dan 0.191/j kadar penggunaan substratum, (qs). Berdasarkan analisis MATLAB
®
 
untuk kajian kinetik biotransformasi yang dilakukan, nilai Vmax, Km dan Ks yang 
diperolehi masing-masing ialah 2.23 mM/j, 76.69 mM and 0.21 mM. 
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OPTIMISING THE PRODUCTION OF CHIRAL ALCOHOL VIA 
ASPERGILLUS NIGER CATALYSED BIOTRANSFORMATION OF 1-(4-
BROMO-PHENYL)-ETHANONE 
 
ABSTRACT 
 
Chiral alcohols are useful starting materials for the synthesis of various 
biologically active compounds. In this study, the biocatalytic reduction of ketone via 
asymmetric reduction process using Aspergillus niger as a whole-cell biocatalyst was 
carried out in order to produce (R)-1-(4-bromo-phenyl)-ethanol. From the result 
obtained in this sudy, it shows that the exponential phase was the best period for 
biotransformation to take place compared to the stationary phase, since the 
production rate (0.063 mM/h) at exponential phase was higher than the production 
rate (0.028 mM/h) at stationary phase. In addition, the optimization study for 
biotransformation via shake-flask system shows that the optimum condition was 
found to be at 48
th
 hr incubation time under pH 6.68 and at 31.85
o
C with the lowest 
amount of substrate concentration which is 6.78 mM. The highest % enantiomeric 
excess and product conversion which almost 100 % were achieved at this optimum 
condition. The increasing amount of substrate concentration used in this 
biotransformation process leads to substrate inhibition. In addition by using the 
bioreactor system, it can maximize the % of enantiomeric excess, production 
conversion, and rate of product formation. The parameters varied on bioreactor 
system were agitation speed in the ranges of 50 rpm to 150 rpm and the incubation 
time of biotransformation from 0 to 56
th
 h. From result obtained, the maximum 
agitation speed was found to be at 150 rpm with optimum incubation time at 33.34
th
 
xxiv 
 
hr of biotransformation with 99.94 % e.e and 88.22 % product conversion. In 
addition, almost 0.097 mM/h of the production rate was achieved at this optimum 
condition. Therefore, from the result obtained it clearly showed that there was quite a 
different range of production rates as well as product conversion of (R)-1-(4-bromo-
phenyl)-ethanol when using the bioreactor system. The optimum incubation time also 
can be shortened compared to the shake-flask system. The result obtained from the 
bioreactor system can be used for further study in verifying the different types of 
substrate used, different aeration and different types of biocatalyst. Besides that, for 
the fermentation kinetic study, the specific growth rate, (µ) of A. niger is 0.29 h
-1 
with 0.164 h
-1
 of product formation rate, (qp) and 0.191 h
-1
 of substrate utilization 
rate, (qs). In addition, according to MATLAB
®
 analysis for the biotransformation 
kinetic study, the values of Vmax, Km and Ks were found to be at 2.23 mM/h, 76.69 
mM and 0.21 mM, respectively. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Research Overview 
1.1.1   Significance of Chirality 
  Molecular chirality is a fundamental phenomenon that plays an important role 
in biological processes. The increasing popularity of chirality in pharmaceutical 
activity has stimulated an increasing demand for economical and high productive 
methods for commercial synthesis of pure enantiomers. The demand for these 
optically pure therapeutic agents is becoming more stringent due to its more-specific 
characteristics compared to any racemic mixtures (Long et. al., 2002; Hassan and 
Mohamed, 2004). In addition, the demand for fast-growing drug industries for 
enantiomerically pure compounds and specialty chemicals are the driver for many 
companies to pursue biocatalytic technology. Enantiomerically pure alcohols are 
valuable chiral building blocks for many such industrials where the compounds act 
as key intermediates in the production of pharmaceuticals, fine chemicals and natural 
products. Recently, much attention has been focused on the production of chiral 
alcohols since the chiral drugs are major contributors to the global pharmaceutical 
market (Long et. al., 2005; Pękala et. al., 2007). 
 
  In addition, the issue of chirality has emerged as a major theme in drug 
design, discovery and development, since stereoisomer distinction is a significant 
component in many pharmacological events. The advances in chiral technology and 
the ability to produce enantiomerically pure compounds have an important impact on 
drug design, research and development as well as on the strategies and policies of the 
pharmaceutical industry (Agranat and Caner, 1999). In the early twentieth 
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century,the relevance of chirality to the pharmaceutical industry was established by 
the fact that one enantiomer of hyoscyamine possessed greater pharmacological 
activity than the other. Today, most of the new drugs and those under development 
consist of a single optically active isomer (Wei et. al., 2009). In addition, regulatory 
agencies throughout the world are currently reviewing the importance of chirality 
since it has becoming an issue for agrochemical, pharmaceutical and other industries 
such as flavor and fragrance industry (Challener, 2002; Leffingwell, 2003). Besides, 
chiral therapeutics or chiral drugs already made up over one-third of pharmaceutical 
drugs currently sold worldwide. This is a growing industry with global chiral drug 
sales for 2002 increasing by 12 % to $160 billion of a total drug market of $410 
billion as reported by Technology Catalysts International (Chirality, 2004). 
 
 The earliest recognition of chirality in drugs was closely linked to the 
discovery of molecular chirality.  As well, drug chirality is now a major theme in the 
design, discovery, development, launching and marketing of new drugs chiral 
molecules are constituents of a large proportion of therapeutic agents (Caner et. al., 
2004). This discovery was accomplished mainly in France during the first half of the 
19
th
 century. By the beginning of the 20
th
 century, investigation of the role of 
chirality in drug action had begun and continued to occupy pharmacologist and 
chemist during the remainder of century. As a result enantioselectivity in the effects 
or character of chiral drugs was found in many cases, especially in a large variety of 
pharmacological effects and chemical structures (Caner et. al., 2004 and Welch, 
2004). Besides, vast majority of synthetic chiral drugs introduced by 1987, where 88 
% were racemic and by the late 1980s roughly a quarter of the drugs on the market 
were chiral and racemic (Francotte and Lindner, 2006). 
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  In addition, chirality is a key factor in the safety and efficiency of many drug 
produced. Meanwhile, chiral alcohols are useful as a starting material for the 
synthesis of various biologically active compounds and thus, the production of single 
enantiomers of drug intermediates has become increasingly important in the agrochemical as 
well as pharmaceutical industries (Patel, 2002; Kurbanoglu et. al., 2007). Many familiar 
drugs were introduced to the market as single enantiomers such as Levothyroxine, 
Paroxetine, Setraline, and to mention a few which as illustrated in Figure 1.1.  
 
 
 
Figure 1.1: Available familiar drugs that market as single enantiomers. 
 
  In fact, single enantiomers can be produced by chemical or chemo-enzymatic 
synthesis. Biocatalysis often offers advantages over chemical synthesis since 
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enzyme-catalyzed reactions are often highly enantioselective and regioselective 
(Patel, 2002). Furthermore, great attention has been paid to enantioselective 
syntheses of enantiomerically pure compounds or chiral synthons that are 
increasingly in demand for the development of modern drugs and agrochemicals 
(Baldassarre et. al., 2000). In addition, chiral alcohols with additional functional 
groups are promising building blocks for the synthesis of enantiomeric pure 
pharmaceuticals and other chemicals (Shimizu et. al., 1998). Chiral alcohol such as 
(R)-1-(4-bromo-phenyl)-ethanol is one of the important precursors or key 
intermediate that normally used in pharmaceutical for drug synthesis.  
 
1.1.2 Biotransformation of Chiral Alcohol 
 Biotransformation has been accepted as a method for generating optically 
pure compounds and for developing efficient routes to target compounds. 
Biotransformation also provides an alternative to the chemical synthetic 
methodology that is sometimes competitive, and thus represents a section of the tools 
available to the synthetic chemist (Loughlin, 2000). As well, according to Xiao and 
co-workers, biotransformation using growing cells is still a preferable method for the 
synthesis of most of the cofactor-dependent products industrially (Xiao et. al., 2005). 
The biotransformation is bound to condition which can significantly affect the 
enantioselectivity and productivity of the chiral alcohol which some of them 
includes; the pH of the media, temperature of the media, incubation time, and 
substrate concentration. The advantages offered by biotransformation over chemical 
catalysis are summarized in Table 1.1. 
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Table 1.1: Comparison between biotransformation and chemical catalysis 
Biotransformation  Chemical catalysis 
Product specificity Product with racemic mixtures 
Environmental friendly Used heavy metal catalysts 
Operated at mild condition Operated at high temperature and pressure 
Acknowledged as ‘natural’ Acknowledged as artificial/synthetic 
 
 In addition, biotransformation has been applied in various industries due to 
the two main reason which includes; i) the availability of microorganism such as 
bacteria, in order to produce large amounts of biomass and a great variety of different 
enzymes in a short time and also; ii) biotransformation offers a product with 
outstanding properties of chemo, regio and stereospecificity. Chemospecificity refers 
to a restricted single chemical reaction when several functional groups present at the 
compound’s structure, and thus, will avoid the side reaction. Meanwhile 
regiospecificity indicates that the reaction of substrate molecules at the same time 
with enzyme while stereospecificity can be described as the enzyme preference to 
attack with one of enantiomers from two entities of R-or S- configuration resulted in 
a single enantiomer compound, thereby avoiding difficulties of racemic mixtures 
(Leuenberger, 1990; Leresche and Meyer, 2006; Arifin, 2010). 
 
 Among the current methodologies that have been applied to obtain chiral 
alcohols include the biocatalytic reductions of the corresponding ketones, as well as 
the kinetic resolution with lipases of the racemic alcohols via esterification 
(Goldberg et. al., 2007). In addition, the reaction of acetophenone to chiral phenyl-
ethanol has been widely studied as a model of reaction for ketone bioreduction. 
Normally the synthesis of optically active alcohols was performed by asymmetric 
reduction of ketone through biocatalytic methods (Brzezińska-Rodak et. al., 2006; 
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Chen et. al., 2008). The enantioselective reduction of ketones in organic synthesis 
plays a major role in the production of  chiral intermediates which can be modified 
later for the synthesis of fine chemicals (Valadez-Blanco and Livingston, 2009). 
Asymmetric reduction of substituent of acetophenone to a chiral phenyl-ethanol 
using the whole-cell biocatalyst is one of the most successful and popular 
applications of biotransformation. This is due to their small sizes, bacteria are by far 
have the largest surface-to-volume ratio in the living world, which allow them to 
maximize their metabolic rates because of a high exchange of molecules and 
metabolites through their surface. This metabolic flexibility requires that these 
microorganisms are also able to produce hundreds of different enzymes for all sorts 
of reactions. Figure 1.2 shows the example of microbial strains used as biocatalyst 
for the conversion of acrylonitrile to acrylamide. 
 
 
 
Figure 1.2:  The photograph on the bacterium belongs to the genus Rhodococcus, a 
polymorphic organism able to grow into very long filamentous 
(Leresche and Meyer, 2006). 
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1.2 Problem Statement 
 In this new millennium, the pharmaceutical industry faces new opportunities 
created by the completion of the Human Genome Project and the increased emphasis 
on genomics and proteomics in drug discovery. Technological advances have 
focused on the drug discovery effort towards the search for drugs directed at 
molecular targets or pathways believed to have a causal role in the disease (Koh et. 
al., 2003). The chiral alcohols are important intermediate for numerous drug in 
pharmaceutical, flavours and fragrance and also play an important role in many 
biological reactions inside human body. Both isolated enzyme and whole-cells have 
been used on laboratory scale and industrially as biocatalyst (Rozzell, 1999; 
Baldassarre et. al., 2000; Milagre et. al., 2008). Furthermore, for the ideal 
biotransformation process, the efficient and stable biocatalyst need to be chosen in 
order to get the highest % enantiomeric excess (% e.e) and product conversion, to 
minimize the side reaction and also to ensure the biocatalyst stable under the optimal 
reaction conditions (Burton, 2001). 
 
There are various whole-cell microorganisms that can be used as a biocatalyst 
for the production of chiral alcohol such as Escherichia coli, Saccharomyces 
cerevisiae, Aspergillus niger, Pseudomonas fluorescens and to mention a few but the 
S. cerevisiae (baker’s yeast) has widely been chosen by many researchers since its 
availability, simplicity to use as well as gives the highest yield as well as % of 
enantiomeric excess compared to other microorganism as mention in Table 1.2 
(Lorraine et. al., 1996; Gervais et. al., 2003; Guo et. al., 2005; Brzezinska-Rodak et. 
al., 2006; Lin et. al., 2008). Meanwhile, the Aspergillus niger is rarely being used as 
biocatalyst for biotransformation of chiral alcohol. Only a few of studies such as 
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done by Demyttenaere et al., (2001); Snajdrova et. al., (2004); Kurbanoglu et. al., 
(2007) and Zilbeyaz et. al., (2008) used A. niger as biocatalyst. Therefore, in this 
present project the wild-type of A. niger ATCC 6275 has been chosen as a 
biocatalyst in order to know how efficient this microorganism affects on the 
production of (R)-1-(4-Bromo-phenyl)-ethanol. 
 
Table 1.2: Whole-cell biocatalyst for synthesis of optically active alpha-hydroxy  
                 acids (Guo et. al., 2005) 
Microorganism Conversion (%) e.e (%) Configuration 
Stenotrophomonas maltophilia 
CECT 112 
90 49 S 
Corynebacterium 
flaccumfaciens CECT 5039 
94 71 S 
Camdida boidinii CECT 10139 72 94 R 
Pseudomonas fluorescens 
AS1867 
70 97 R 
Saccharomyces ellipsoideus 
JUC Y 
82 >99 R 
Saccharomyces cerevisiae 
CECT 1929 
88 >99 R 
Saccharomyces cerevisiae 
CECT 1477 
93 >99 R 
Saccharomyces cerevisiae JUC 
WXJ-2 
98 >99 R 
 
In fact, normally biotransformation was carried out at exponential phase 
without knowing the effect at different phase such as during stationary phase on the 
% e.e as well as product conversion. The fermentation process usually stops and 
produces lower cell biomass at stationary phase but the biotransformation process 
might be occurred and produces the chiral alcohol during that phase. Therefore, the 
biotransformation process needs to be investigated during stationary phase too and 
the efficiency of A. niger also could be investigated during both phases. Besides, the 
effect of incubation time for the shake-flask and bioreactor system should be 
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scrutinized in order to ensure which system shows the best incubation time as well as 
produces the highest % e.e, product conversion and production rate. 
 
In addition, most of the biotransformation of chiral alcohols was not being 
optimized and in order to get the optimum condition, they only verified the effect of 
each parameter such as incubation time, pH, temperature, agitation speed and to 
mention a few. However, the relationship between each parameter involved which 
includes; incubation time, pH, temperature, agitation speed, as well as substrate 
concentration and the profile for every parameter at optimum condition has not being 
verified by the most researchers. The optimization and the relationship between each 
parameter can be verified by using response surface methodology (RSM) in order to 
get the highest % e.e as well as product conversion at optimum condition. Moreover, 
biotransformation system can be characterized biochemically in order to provide the 
information which then can be used in mathematically modelling and also scale-up 
of the bioreactors (Burton, 2001). The growth kinetics of A. niger and modelling for 
the biotransformation of (R)-1-(4-Bromo-phenyl)-ethanol need to be investigated too, 
since there might be the substrate inhibition occurred in the biotransformation 
process. This is due to the kinetics and modelling for the substrate inhibition that 
occurred previously in the study done by Zilbeyaz and Kurbanoglu, (2008) has not 
been carried out. In fact, the substrate concentration in the bio-medium is of 
paramount importance in the performance of biotransformation since in many cases, 
it will inhibit the biocatalyst activity as well as affecting the enantioselectivity of the 
product (Valadez-Blaco and Livingston, 2008). The kinetic and modelling actually is 
important to find the value of Vmax, Km, and Ks.  
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1.3 Research Objective 
  In order to achieve the overall aims, several specific objectives were defined: 
i) To study the efficiency of A. niger as a biocatalyst at different growth phase 
in the reduction of ketone to chiral alcohol for the synthesis of chiral drug. 
ii) To determine the optimum pH, temperature and substrate concentration in 
order to obtain the maximum % enantiomeric excess as well as production of 
chiral alcohol via shake-flask system using response surface methodology 
(RSM). 
iii) To identify the optimum incubation time and agitation speed using 2.5 L 
bioreactor system and to compare the formation rate between shake-flask 
study and bioreactor system. 
iv) To obtain the kinetic growth of A. niger and the model for the production of 
(R)-1-(4-bromo-phenyl)-ethanol using POLYMATH
®
 and MATLAB
®
. 
 
1.4 Organization of the Thesis 
  This thesis consists of six chapters in which every chapter describes the 
sequence of the research and represents valuable as well as tangible information 
about the research study.  
 
  Chapter 1 briefs the term of chirality, the history and the application of the 
chirality in pharmaceutical field. It also concisely described the market trends 
throughout the world and the techniques available in order to obtain the chiral 
alcohol. The problem statements, research objectives and the organization of thesis 
were also highlighted in this chapter. 
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  Chapter 2 represents the details of every subtopic that are related to the 
biotransformation of the chiral alcohol. It also covers the advantages of using 
whole-cell microorganism as biocatalyst for the biotransformation of ketone to 
chiral alcohol. The general schematic process of reduction was also described here.  
 
  Chapter 3 emphasizes on the materials and method used, which also 
describes the procedures for the production of chiral alcohol using A. niger as a 
biocatalyst via shake-flask method. This chapter also explains the analytical 
method, kinetic and modeling, and optimization studies for every biotransformation 
parameters. The overall experiment flow chart was also presented here. 
 
  Chapter 4 refers to the experimental result and details discussion of the 
fermentation growth of A. niger and also the results of biotransformation of (R)-1-
(4-bromo-phenyl)-ethanol for every parameters studied.  
 
  Chapter 5 discusses about the kinetics and modeling of A. niger growth and 
biotransformation of (R)-1-(4-bromo-phenyl)-ethanol by using POLYMATH
®
 and 
MATLAB
® 
analysis. 
 
  Chapter 6 summarizes and concludes the overall finding based on the results 
obtained in the previous chapter. The recommendations for future studies are also 
given here. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1    Chirality  
2.1.1 The Term of Chirality 
Chirality is well known as the key factor in the efficiency of many drugs and it 
also plays an important part in human life. In fact, it is an essential property of the 
bio-molecular building blocks of life (Young et. al., 2006). The concept of "chirality" 
has been known in chemistry since the 1870's although it would be nearly a hundred 
years before chemists began using the term. In simple words, chirality is "handedness," 
that is, the existence of left/right opposition. For example, the left hand and right hand 
are mirror images and therefore "chiral". The term chiral is derived from the Greek 
word kheir meaning "hand" and it is used to express an object that is non-superposition 
on its mirror image (Leffingwell, 2003). In addition, any carbon atom that is bonded 
to four different functional groups is termed as a chiral or an asymmetric carbon. 
Molecules containing one or more of these carbon centers are considered as chiral 
molecules. Chiral centers can exist in two forms called enantiomers (R and S). Figure 
2.1 shows a few examples of chiral molecules. 
 
 
Figure 2.1: Examples of chiral molecules. 
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2.1.2 Application of Chirality in Industries 
The importance of chirality in life sciences and the production of new materials  
has been growing rapidly, and is highly appreciated by the pharmaceutical industry 
for decades. This makes the manufacturing of chiral molecules one of the highlighted 
topics in modern fine chemical industry (Akutagawa, 1995). As technologies for 
producing and measuring enantiopure materials keep improving, the production of 
enantiopure pharmaceuticals has become commonplace, with many of the top selling 
drugs in the world are now being sold in enantiopure forms. Consequently, the 
subject of chirality in  pharmaceutical industries is a topic of considerable interest 
and importance (Welch, 2004; Nguyen et. al., 2006; Mohan et. al., 2011).  Apart 
from that, chirality continues to attract interest in the chemical, biological and 
pharmaceutical sciences. Nowadays, chiral synthesis is becoming increasingly 
important for research and development in other various applied industries. It is even 
more important to synthesize these enantiopure products in an environmentally 
friendly process in order to build a sustainable society (Nakamura et. al., 2002; 
Hasan et. al., 2004). 
 
2.2     Single Enantiomer  
2.2.1  Single Enantiomer of Chiral Molecule 
Chiral molecules such as amino acids, sugar, proteins and nucleic acids are  
important components in all living organisms. An interesting feature of these chiral 
bio-molecules is that, they naturally exist in only one of the two possible 
enantiomeric forms (R or S). However, only a single enantiomer of a chiral molecule 
is usually desired, as is the case when the target molecule is a chiral drug that will be 
used by both human and animals. Drug molecules can be likened to tiny keys that fit 
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into locks in the body and elicit a particular biological response. Since the „locks‟ in 
living organisms are chiral, and exist in only one of the two possible enantiomeric 
forms, only one enantiomer of the „key‟ molecule should be used (Welch, 2004; Cox, 
2005; Mohan et. al., 2011; Nagori et. al., 2011).   
 
Indeed, many of the major pharmaceutical manufacturers are seeking more 
efficient and cleaner routes in order to produce single enantiomeric compounds, 
either in the form of drug intermediates or active pharmaceutical ingredients. Among 
the 100 top-selling drugs in today‟s market, 50% are single enantiomer drugs. The 
production of single enantiomers of drug intermediates is increasing and many 
biologically active substances exist as single enantiomers in living organisms 
(Misl'anová and Hutta, 2003; Patel, 2006). Enantiomers can have different biological 
activities which determine the efficacy of the compound. The use of enantiomerically 
pure drugs in chemotherapy is becoming mandatory, not only to realize the enhanced 
specificity of the drug‟s action but also to prevent any possible toxicity and 
undesirable load on the patient‟s metabolism by the other enantiomer (Sonawane et. 
al., 1991; Islam et. al., 1997; Creagh et. al., 2004; Webster, 2006; Sweet, 2009; 
Peeplwala et. al., 2010).  
 
In addition, chiral compounds are typically optically active where they often 
have one or more chiral centers. It has been reported that more than one-half of 
marketed drugs are chiral (Misl'anová and Hutta, 2003; Jurcek et. al., 2008). In the 
meantime, the methodologies for preparing optically active compounds have been 
available for over a 100 years which includes; crystallization, liquid chromatography 
and kinetic resolution, to mention a few. Furthermore, a wide variety of techniques 
15 
 
for chiral separations have been developed in the past 15 years (Rekoske, 2001). 
Normally, the enantiomers can be separated by conventional methods, such as 
crystallization, chromatography on silica or other stationary phases. Chromatography 
is a process that often resulted in high enantiomeric excess which it is suitable on an 
analytical scale, but its scale-up can be difficult. In this present project, the High 
Performance Liquid Chromatography (HPLC) technique has been chosen in order to 
separate the enantiomers.  
 
2.2.2  Development of Single Enantiomer in Industries 
According to Patel (2002), single enantiomers can be produced through a 
chemical or chemo-enzymatic synthesis. However, biocatalysis offers better 
advantages over chemical synthesis as enzyme-catalyzed reactions are often highly 
enantioselective and regioselective. Thus, the synthesis of optically active alcohols is 
normally performed by asymmetric reduction of ketone through biocatalytic methods 
(Chen et. al., 2008). Moreover, according to Wei et. al. (2009), the enantiomers of a 
chiral drug are usually different in their physiological activities whereby one 
enantiomer is only effective to cure a disease, while the other one may be less 
effective, ineffective or even toxic if consumed. Hence, chiral drugs need to be 
carefully separated into single enantiomers during their development and production 
processes. Thus, enantio-separation is very important for the pharmaceutical industry 
and it has attracted many researchers‟ attention to develop effective enantio-
separation techniques (Wei et. al., 2009). Indeed, single enantiomer drugs continue 
to take an increasing share in the market with worldwide sales of these drugs surging 
by 21 % between 1996 and 1997 up to almost $90 billion (Gervais, 2003). Sandra 
(2006) reported that based on estimates from Technology Catalysts International 
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(Falls Church, VA) and IMS Health, single enantiomer therapeutics had sales of 
$225 billion in 2005,  representing 37 % of the total final formulation pharmaceutical 
market of $602 billion. Figure 2.2 shows the examples of single enantiomers 
currently available in the market (Hutt and Valentová, 2003). 
 
 
 
 
 
 
 
Figure 2.2: Marketed single enantiomers which have undergone the chiral switch 
(Hutt and Valentová, 2003). 
 
In addition, the compound annual growth rate for single enantiomer products 
over the past five years is 11 %, which is on par with the pharmaceutical market as a 
whole. The chiral switch process has resulted in a number of agents being re-
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marketed as single enantiomer products. Chiral switch can be defined as the 
development of a single enantiomer from a previously marketed racemate. 
Furthermore, single enantiomer drugs will grow at a similar rate as the overall 
pharmaceutical market. Higher growth in key therapeutic categories will be offset by 
the large and maturing markets in antibiotics and cardiovascular drugs. Parts of the 
higher growth will be from sales increase in biologics, but the use of small molecules 
in certain key classes such as cancer, arthritis, central nervous system and antiviral 
will give significant impacts as well (Sandra, 2006).  
 
2.3     Chiral Alcohol as Chiral Drug 
2.3.1  Market View of Chiral Alcohol 
Among the various chiral compounds, chiral alcohols represent a highly 
versatile and attractive group of chiral building blocks for the synthesis of various 
drugs (chiral synthons) and drug intermediates (Soni and Banerjee 2005). Chiral 
alcohols are the most important kinds of chiral building blocks for many 
pharmaceuticals, due to their structural property (Zilbeyaz et. al., 2009). The 
enantiomers administered as drugs often have different actions, toxicities and 
pharmacokinetic properties (what body does to the drug)  due to the macromolecular 
substances such as enzymes and receptors have inherent chiral selectivity in 
biological systems (Yang et. al., 2008).  
 
Chiral technology has driven major developments in the pharmaceutical 
industry, which involves more than just chiral drugs. The emphasis is mainly focused 
on producing low-volume with high-value products. Chiral drugs continue to be a 
significant force in the global pharmaceutical market. According to Stinson (2000), 
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worldwide sales of single-isomer drug accounted for 30 % of the $335 billion total 
drug sales worldwide in 1998, edging up to 32 % of the $360 billion market in 1999. 
In addition, according to Smith, (2000), single enantiomer compounds are the major 
component of the largest selling brands, in both absolute number of drugs and dollar 
sales volume. Furthermore, Challener (2002) reported that the total sales of chiral 
drugs had reached $147 billion in 2001 which is an increasing of 3.6 % over the total 
drug sales in 2000. Besides, government agencies, such as the US Food and Drugs 
Administration (FDA)  have recommended that all new asymmetric drugs being 
marketed should be a single enantiomer (Agranat and Caner, 1999; Gervais, 2003). 
Table 2.1 shows the global chiral drug sales from the year 1998 to 2000.  
 
Table 2.1: Global chiral drug sales from year 1998 to 2000 (Smith et. al., 2000). 
 GLOBAL SALES ($) 
$ Millions 1998 1999 2000 
Cardiovascular 21,906 24,805 26,012 
Antibiotics/antifungal 19,756 20,907 23,265 
Hormones/endocrinology 12,297 13,760 17,345 
Cancer 8,006 9,420 13,360 
Central nervous system 7,027 8,592 13,720 
Haematology 6,730 8,580 11,445 
Antiviral 6,131 7,540 13,446 
Respiratory 4,305 5,087 8,795 
Gastrointestinal 1,718 2,998 5,355 
Ophthalmic 1,482 1,794 2,070 
Dermatological 1,124 1,270 1,540 
Analgesics 842 1,045 1,135 
Vaccines 568 676 1,100 
Other 7,947 8,527 7,425 
TOTAL 99,839 115,001 146,013 
 
These sales value hit over $100 billion worldwide and increases steadily from 
one year to another, indicating an increasing demand for optically pure therapeutic 
agents as the result of its target specific characteristic than racemic mixtures. This 
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awareness has led to heightened efforts to obtain optically pure compounds (Smith, 
2000; Stinson, 2000). 
 
2.3.2 The Importance of Chiral Alcohol 
Chiral building blocks could be naturally occurring substances or simple and 
readily available chiral compounds that could be directly utilized in the synthesis of 
more complex target molecules (Shen, 2009). In fact, the demand for chiral alcohols 
has boosted since the need for optically active drugs has increased in the 
pharmaceutical and agrochemical fields in recent years. Due to this situation, chiral 
alcohols are becoming increasingly vital as a bioactive compound; being utilized as 
ligands for various metals in a number of asymmetric reactions (Moon Kim and Jin 
Kyoon, 1999; Kurbanoglu et. al., 2007). Likewise, it is very important in the 
pharmaceutical industry since enantiomers of drug compounds may possess different 
pharmacological and toxicological properties (Zhou et. al., 2009).  
 
Currently, several methodologies can be applied in the process of synthesizing 
chiral alcohols such as the asymmetric reduction of prochiral ketones, the 
enantioselective oxidation of a single isomer from its racemate as well as the 
enantioselective reduction of a carbonyl group using enzymes such as alcohol 
dehydrogenase or whole-cell microorganism as a biocatalyst (Hasegawa et. al., 1996; 
Kurbanoglu et. al., 2007). According to Williams et. al., (2001), these methodologies 
are important in order to measure chiral purity, chiral stability of a drug substance 
and its stability in metabolism. Chiral alcohols can be efficiently synthesized via 
asymmetric reduction of the corresponding prochiral carbonyl compounds using 
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biocatalysts such as oxido-reductase or whole cells (Yang et al., 2008). Scheme 2.1. 
shows a few examples of chiral alcohol syntheses previously studied by researchers. 
 
 
 
i) Reduction of cyclic ketones (tetralones) using Daucus carota (Yadav et. al., 
2007). 
 
 
 
ii) Reduction of perfluorinated ketones with alcohol dehydrogenases (enzyme) 
(Rosen et. al., 2006). 
 
 
 
iii) Reduction of 4-benzyloxy-3-methanesulfonylamino-2‟ bromo-acetophenone 
2 to (R)-alcohol (Patel, 2001). 
 
Scheme 2.1 :  Examples of chiral alcohol syntheses via reduction of various ketones 
(Yadav et.  al, (2007); Rosen et. al, (2006); Patel, (2001)). 
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2.3.3  Asymmetric Synthesis in Chiral Alcohol 
Asymmetric synthesis, also known as chiral synthesis is an organic synthesis 
which introduces one or more new and desired elements of chirality. Gladiali, (2007) 
reported that the birth of asymmetric synthesis already exist in 1890, when Emil 
Fischer recognized that the addition of hydrogen cyanide to L-arabinose had resulted 
in some 75 % yield of one of the two possible diastreomeric cyanohydrins. In 
addition, according to Akutagawa (1995), under certain conditions, asymmetric 
synthesis allows the production of enantiomerically pure compounds that have a 
wide range of applications in industry. Chemists have fully recognized the 
importance and practicality of asymmetric synthesis in various fields such as in 
synthetic organic chemistry, medicinal chemistry, natural products chemistry and 
pharmaceutical industries. The rise in its importance is due to the development of 
newer and more efficient methods during the last decade (Ojima et. al., 1998). 
Scheme 2.2 shows a generic example of an asymmetric synthesis process. 
 
 
Scheme 2.2: Example of asymmetric reduction of ketone to alcohol using Daucus 
carota as bioctalyst (Kaluzna et. al., 2005). 
 
 
From Scheme 2.2, it shows that the asymmetric reduction process using 
Daucus carota can regenerate the cofactor itself in order to produce the chiral 
alcohol continuously. The product produced will be either R or S. The asymmetric 
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reduction of ketone is one of the most important fundamental and practical reactions 
for producing non-racemic chiral alcohols without racemization in order to 
synthesize industrially important chemicals (Yadav et. al., 2007). The catalysts for 
the asymmetric reduction of ketone can be classified into two categories: chemical 
and biological. Both methods have their own peculiarities and further development in 
selecting the appropriate catalysts for specific purposes is necessary to promote green 
chemistry (Nakamura et. al., 2003). There are various types of useful ketone used as 
substrate for the asymmetric reduction process such as an aromatic hydroxyl ketone 
(1), α-alkyl substituted 1,3-diketones (2), and α- and β-alkyl substituted β-ketoesters 
(3). The structures of each ketone mentioned are presented in Figure 2.3. 
 
 
Figure 2.3: Several of ketone used as a substrate in asymmetric reduction process 
*Ph=phenyl, (Kaluzna et. al., 2005). 
 
Furthermore, the asymmetric reduction of ketones to alcohols introduces 
chirality into a target molecule, which can be used as a valuable intermediate in the 
preparation of chiral drugs (Brzezińska-Rodak et. al., 2006). Asymmetric synthesis 
has emerged as one of the most rapidly developing research areas in organic 
chemistry. Among various strategies involved in the asymmetric synthesis include; 
the extensive studies of the use of chiral auxiliaries as well as chiral ligands. A 
number of new auxiliaries and ligands have been successfully utilized for efficient 
asymmetric synthesis (Moon Kim and Jin Kyoon, 1999). Furthermore, the 
modification of ligand has played a key role in developing new catalyst precursors 
for asymmetric synthesis (Zhang et. al., 2009). 
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2.4    Biocatalysis 
2.4.1 Biocatalysis in Industries 
Despite tremendous scientific and technical advances, several chiral syntheses 
still remain difficult and expensive. Due to this situation, asymmetric biocatalysis 
employing whole microorganisms has often emerged as a viable alternative 
(Chartrain et. al., 2001). Biotechnology offers many possibilities for new medical 
therapies and the manufacturing of new pharmaceuticals, including the synthesis of 
small molecule pharmaceuticals via biocatalysis is one of the challenging works 
(Woodley, 2008). A significant breakthrough in the field of biocatalysis came in the 
late 1950s, when the first three-dimensional enzyme structure was resolved with the 
help of X-ray analysis (Yuryev and Liese, 2010). Nowadays, the industrial 
biocatalysis is apparently experiencing a noteworthy growth and gaining momentum 
especially in the process of synthesizing pure compounds for pharmaceutical 
intermediates. This phenomenon is hardly surprising considering the enhanced 
integration of biological catalysts into a variety of industrial processes ranging from 
manufacturing commodity chemicals to synthesizing highly complex pharmaceutical 
intermediates and drug substances (Zaks, 2001; Panke and Wubbolts, 2005).   
 
The role of biocatalyst in an asymmetric synthesis continues to become more 
vital, from a miniaturized micro process to a large-scale macro process. Applying 
biocatalysis to industrial processes has been shown to be a very advantageous 
alternative to the conventional chemical methods. Recently, it has also been widely 
used to prepare enantiomerically pure pharmaceuticals and other compounds of 
interest. Moreover, biocatalytic approaches using microbial cells and enzymes have 
become attractive choices for the synthesis of chiral compounds, thanks to the 
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developments in the discovery, expansion and production of stable biocatalysts. All 
these developments have brought about new designs for biocatalytic processes in 
product purification as well as recovery. This is also due to the advances in 
genomics, screening and evolution technologies, leading to increase availability of 
new and robust biocatalysts suited for industrial-scale application (Panke and 
Wubbolts, 2005; de Gonzalo et al.,2007; Wohlgemuth, 2010). 
 
Indeed, biocatalysts are responsible for the chemistry of life which includes 
controlling chemical transformations in primary metabolism and assisting the 
generation of natural product diversity in secondary metabolism of plants and 
microbes (Walsh, 2001). Nowadays, various chiral alcohols can be produced via 
biocatalysis using two methods, that include; a kinetic resolution of the racemic 
starting material and secondly, a direct synthesis from a prochiral compound. In 
many cases, highly enantio-selective reduction can be achieved when biocatalysts are 
used. Both isolated enzymes and whole cells can be utilized as biocatalysts (Pekala 
et. al., 2007). The application of biocatalyst for preparing molecular asymmetry has 
led to the higher enantioselectivity, product yield as well as efficiency and therefore, 
it is currently experiencing a worldwide renaissance (Wohlgemuth, 2010).  
 
In fact, an important element in developing biocatalyst is the identification of 
the required enzyme activity, in terms of the desired chemical reaction‟s substrates 
and products and thereafter, identifying the source of such enzyme activity. Once a 
suitable source has been found, an efficient production system for the enzyme would 
be required. In a typical conventional biocatalysis process, the cell would be grown 
in a fermentation system, then harvested and used as whole-cells or the enzymes 
